Specialty Pharma Journal Specialty, Precision & Technology
BOSTON & OXFORD, United Kingdom–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and …
Tag Archives: collaboration
August, 2018
-
29 August
Horizon Discovery Announces Collaboration with Major Pharma Company on Single Cell RNAseq-Linked CRISPR Screening
CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company”, or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification …
June, 2018
-
27 June
AbbVie and Calico Extend Collaboration for Development of Therapies for Age-Related Diseases
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 26, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today announced an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and …
April, 2018
-
25 April
Nektar and Takeda Collaborate to Evaluate Potential Clinical Benefits of Two Novel and Complementary Immuno-Oncology Mechanisms
SAN FRANCISCO, April 24, 2018 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential combination treatment regimen in multiple cancer settings. NKTR-214 is …
January, 2018
-
31 January
SkylineDx and Mayo Clinic Enter Strategic Collaboration to Develop Diagnostic Tests for Melanoma
ROTTERDAM, Netherlands, Jan. 31, 2018 /PRNewswire/ — SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop …
May, 2017
-
22 May
Nektar and Takeda Enter Research Deal Exploring Combination Cancer Therapy Approaches
SAN FRANCISCO, May 22, 2017 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of Nektar’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda’s cancer portfolio. The …
April, 2017
-
28 April
Takeda and Harrington Collaborate for Development of Rare Disease Drugs
Osaka, Japan and Cleveland, Ohio, USA – 27 April 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502), and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases. A first of a kind partnership for Harrington Discovery Institute …
November, 2015
-
3 November
Sanofi and BioNTech Enter an Up to $1.58 Billion Immuno-Oncology Partnership
PARIS and MAINZ, Germany, November 3, 2015 /PRNewswire via COMTEX/ — Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to …
October, 2015
-
13 October
Protalix Sells its Share of its Gaucher Drug to Pfizer for $46 Million
CARMIEL, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company sold its share in the collaboration agreement for ELELYSOTM to its commercialization partner, Pfizer Inc. Under the initial collaboration agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of ELELYSO on a 60%/40% …
April, 2015
-
3 April
BIND and Pfizer Extend Accurins Collaboration
Accurins developer BIND Therapeutics recently announced that it has extended its collaboration with Pfizer. The companies announced an extension of the terms of their global collaboration to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline. The companies’ original collaboration, worth up to …